Yamagami Wataru, Susumu Nobuyuki, Ninomiya Tomomi, Kuwahata Michiko, Takigawa Aya, Nomura Hiroyuki, Kataoka Fumio, Tominaga Eiichiro, Banno Kouji, Tsuda Hiroshi, Aoki Daisuke
Department of Obstetrics and Gynecology, School of Medicine, Keio University, Shinjuku, Tokyo 160-8582, Japan.
Mol Clin Oncol. 2014 Jul;2(4):591-595. doi: 10.3892/mco.2014.272. Epub 2014 Mar 31.
There is currently insufficient evidence to recommend a specific chemotherapeutic regimen as standard treatment for uterine sarcomas. In this study, we investigated the toxicity and effectiveness of ifosfamide, adriamycin and cisplatin (IAP therapy) in patients with progressive and recurrent uterine sarcoma. A total of 11 patients with progressive or recurrent uterine sarcoma containing leiomyosarcoma (LMS), undifferentiated endometrial sarcoma (UES) or adenosarcoma, who were diagnosed at our institution, were retrospectively investigated. We recorded the adverse events, response rate and progression-free survival in these cases. The histological types included LMS (54.5%), adenosarcoma (27.3%) and UES (18.2%). Grade ≥3 leukopenia or neutropenia were observed in all the cases, febrile neutropenia developed in 45.5% of the patients and grade 4 thrombocytopenia developed in 3 cases (27.3%). With IAP therapy, the response rate was 36.4% and the disease control rate was 90.9%. Therefore, IAP therapy may be a viable option as chemotherapy for uterine sarcoma.
目前尚无足够证据推荐特定的化疗方案作为子宫肉瘤的标准治疗方法。在本研究中，我们调查了异环磷酰胺、阿霉素和顺铂（IAP疗法）对进展期和复发性子宫肉瘤患者的毒性和有效性。对在我们机构诊断出的11例患有进展期或复发性子宫肉瘤（包括平滑肌肉瘤（LMS）、未分化子宫内膜肉瘤（UES）或腺肉瘤）的患者进行了回顾性研究。我们记录了这些病例中的不良事件、缓解率和无进展生存期。组织学类型包括LMS（54.5%）、腺肉瘤（27.3%）和UES（18.2%）。所有病例均观察到≥3级白细胞减少或中性粒细胞减少，45.5%的患者出现发热性中性粒细胞减少，3例（27.3%）出现4级血小板减少。采用IAP疗法时，缓解率为36.4%，疾病控制率为90.9%。因此，IAP疗法可能是子宫肉瘤化疗的一个可行选择。
